CD274 and non-small cell lung carcinoma: The results of KEYNOTE 024 [63] showed that patients with advanced NSCLC with high PD-L1 expression (≥ 50%) had better OS, PFS with pembrolizumab compared to conventional chemotherapeutic agents.